Kite, a Gilead Company, are to present latest cell therapy research at 24th Congress of the European Haematology Association (EHA) looking at B-cell malignancies and CAR T therapy.
Taking place from 13-16 June 2019, the 24th Congress of the European Hematology Association will be taking place in Amsterdam, The Netherlands. The meeting will bring together experts from around the world to present new clinical research, exchange knowledge and discuss the latest innovations in the diagnosis and treatment of haematological diseases. Kite will be hosting two scientific symposia with leading experts in the field of cell therapy research, looking at clinical trials in B-cell malignancies and the patient-centric approach to CAR T therapy.
Latest scientific data in the world of cell therapy research
Kite will present the latest scientific data from its cell therapy research programmes in haematological cancers, providing new insights to attending European experts.
The company will also host two scientific symposia with leading experts in the field of cell therapy, below are further details;
- Beyond clinical trials in B-cell malignancies: what real-world evidence tells us; and
- A patient-centric approach to CAR T therapy: from treatment selection to patient management.
Committed to advancing the treatment of haematological cancers
The annual congresses encompass the entire spectrum of haematological studies, where attendees, together with 11,000 other participants who share a passion for this field, can learn about the latest findings and innovations.
The EHA Annual Congress is a forum for:
- Original unpublished data;
- Sharing ideas about haematological innovation; and
- Disseminating evidence-based knowledge of primary clinical relevance.
“We look forward to contributing towards discussions with leading experts at this year’s EHA congress, one of the most important global forums in haematology,” said Dominique Tonelli, MD, Head of Medical Affairs, Europe, Kite.
“Kite remains committed to advancing the treatment of challenging haematological cancers through innovative cell therapies.”